bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S2 from Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ
Authors: Gomez-Roman Natividad , Chong Ming Y , Chahal Sandeep K. , Caragher Seamus P. , Jackson Mark R. , Stevenson Katrina H. , Dongre Sidhartha A. , Chalmers Anthony J.
Published: April 2023

Akt expression in 3D GSC before and after radiation treatment. A, Bar charts representing mRNA expression of Akt, PARP and PTEN genes in G7 and E2 3D cells treated with 0 or 5 Gy. RNA extraction was performed 4 h after irradiation treatment. B, Protein expression of G7 and E2 3D GSC for Akt1, Akt2, Akt3, PARP1 and PTEN treated with 0 or 5 Gy. Cell lysates were prepared 4 h after irradiation treatment. Actin serves as loading control. C, Enrichment analysis of RNASeq data for G7 or E2 3D cells grown in the presence of VEGF comparing no radiation v radiation treatment. Analysis was performed using Biocarta_Akt_Pathway. D. Perifosine dose response (0.1 microM to 10 microM) at 0 and 3 Gy in G7 3D GSC. Cells were treated with respective inhibitor 2 h prior to ionizing radiation. Values were normalized to vehicle (DMSO) against their respective radiation dose. Curves were fitted with a median enhancement effect model. Statistical analysis with one-way ANOVA, *p<0.05; **p<0.005.
Supplementary Figure S1 from Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ
Authors: Gomez-Roman Natividad , Chong Ming Y , Chahal Sandeep K. , Caragher Seamus P. , Jackson Mark R. , Stevenson Katrina H. , Dongre Sidhartha A. , Chalmers Anthony J.
Published: April 2023

Radiosensitisation of G1 and G7 3D GSC by PARP inhibitor olaparib and ATM inhibitor KU55933. A, Determination of secreted VEGF by Elisa assay of media recovered from G7, E2 and R10 3D cells grown at hypoxic (1% O2) and normoxic (20% O2) conditions. Media was collected 48 h after seeding. Data represents means {plus minus} SD from 3 independent experiments performed in duplicate. B, Clonogenic survival efficiency of G1 and G7 GSC grown on 3D conditions after receiving 0 or 3 Gy in a 96-well clonogenic assay. C-E, Erlotinib (C), olaparib (D) and KU55933 (E) dose response (0.1 microM to 10 microM) at 0 and 3 Gy in G1 and G7 3D GSC. Cells were treated with respective inhibitor 2 h prior to ionizing radiation. Values were normalized to vehicle (DMSO) against their respective radiation dose. Curves were fitted with a median enhancement effect model. Statistical analysis with one-way ANOVA, *p<0.05; **p<0.005.
Supplementary Figure 4 from Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Authors: Hingorani Dina V. , Doan Matthew K. , Camargo Maria F. , Aguilera Joseph , Song Seung M. , Pizzo Donald , Scanderbeg Daniel J. , Cohen Ezra E.W. , Lowy Andrew M. , Adams Stephen R. , Advani Sunil J.
Published: April 2023

MMAF anti-HER2 antibody conjugates spatial localization in HER2 negative tumors.
Supplementary Fig S3 from TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
Authors: Ito Kimihiro , Nishio Makoto , Kato Masanori , Murakami Haruyasu , Aoyagi Yoshimi , Ohe Yuichiro , Okayama Takashige , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Gotaro , Nonoshita Katsumasa , Ito Satoru , Matsuo Kenichi , Miyadera Kazutaka
Published: April 2023

Supplementary Fig. S3 shows cytotoxicity of EGFR-TKIs for normal human epidermal keratinocytes.
Supplementary Figures from Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
Authors: Quinn Jeanne M. , Greenwade Molly M. , Palisoul Marguerite L. , Opara Gregory , Massad Katina , Guo Lei , Zhao Peinan , Beck-Noia Hollie , Hagemann Ian S. , Hagemann Andrea R. , McCourt Carolyn K. , Thaker Premal H. , Powell Matthew A. , Mutch David G. , Fuh Katherine C.
Published: April 2023

Supplementary Figures. S1 - AXL and overall survival. High AXL is associated with poor OS. S2 - BGB324 treatment and downstream inhibition. BGB324 treatment inhibits pAXL and downstream activation.
Supplementary Tables3-5,7-9 from Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Authors: Roy Riti , Winteringham Louise N. , Lassmann Timo , Forrest Alistair R.R.
Published: April 2023

Supplementary Table 3a: Molecular Targets of the Anticancer Drugs from GDSC, CTRP and DrugBank. Spearman correlation and permutation testing results are provided for both the GDSC and CTRP datasets. Supplementary Table 4: List of drugs where we observe both a correlated and an anti-correlated target in GDSC and CRTP datasets. Supplementary Table 5: Fractions of single cells in each cell line expressing both targets from Figure 3. Supplementary Table 7: Transcript isoform aware reanalysis of CTRP-GDSC concordance. Spearman correlation values between drug sensitivity and drug-target transcript isoforms expression for 74 drugs common between GDSC and CTRP. The 541 cell lines common in GDSC and CTRP where drug-target transcript isoform expression and AUC values could be obtained were considered. As GDSC and CTRP provide gene-level expression measurements from different microarray versions (Affymetrix GeneChip HG-U133A in GDSC and HG-U133PLUS2 in CTRP), which potentially detect different isoforms of each gene, we repeated our analysis at the transcript level. Supplementary Table 8: The top 20 strongest correlations and top 20 strongest anti-correlations between drug sensitivity and gene expression for the GDSC and CTRP datasets. Supplementary Table 9: Drug-target pairs that are significantly correlated in cell lines derived from a cancer subtype but not significantly correlated in the pan-cancer analysis.
Supplementary Legends from Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Authors: Roy Riti , Winteringham Louise N. , Lassmann Timo , Forrest Alistair R.R.
Published: April 2023

Full listing of supplementary files and their legends
Figure S1 from RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer
Authors: Goka Erik T. , Chaturvedi Pallavi , Lopez Dayrelis T. Mesa , Garza Adriana De La , Lippman Marc E.
Published: April 2023

Figure S1 shows Rac1 expression analysis of Normal Colon and Colon Adenocarcinoma patients obtained from the TCGA COAD dataset using Oncomine. Data is represented as Log2 Median centered ratio.
Supplementary Figure 7 from Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Authors: Disis Mary L. , Corulli Lauren R. , Gad Ekram A. , Koehnlein Marlese R. , Cecil Denise L. , Senter Peter D. , Gardai Shyra J. , Okeley Nicole M.
Published: April 2023

Splenocytes from mice provided normal water (open circle, n=8), 20mM 2FF (closed circle, n=8), or 50mM 2FF (triangle, n=7) for tumor prophylaxis showed a mean {plus minus} SEM IFN-ɣ response toward MMC lysate of 41.7 {plus minus} 6.35 (20mM group, p<0.0001) and 47.8 {plus minus}11.1 CSPW (50mM group, p<0.0001), compared to 5.63 {plus minus} 3.16 spots in untreated animals. The response was not dose dependent (p=0.603). No significant difference was observed for the two groups when stimulated with non-specific peptide HIV (20mM p=0.797; 50mM p=0.985) or Cyclin B1 (20mM p=0.984; 50mM p=0.978 ). ****p<0.0001.
Supplementary Figure S4 from A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
Authors: Reiss Kim A. , Wattenberg Max M. , Damjanov Nevena , Prechtel Dunphy Elizabeth , Jacobs-Small Mona , Lubas M. Judy , Robinson James , Dicicco Lisa , Garcia-Marcano Luis , Giannone Michael A. , Karasic Thomas B. , Furth Emma E. , Carpenter Erica L. , Wojcieszynski Andrzej P. , Vonderheide Robert H. , Beatty Gregory L. , Ben-Josef Edgar
Published: April 2023

Extended analysis of Treg phenotype
Supplementary Figure S3 from A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
Authors: Reiss Kim A. , Wattenberg Max M. , Damjanov Nevena , Prechtel Dunphy Elizabeth , Jacobs-Small Mona , Lubas M. Judy , Robinson James , Dicicco Lisa , Garcia-Marcano Luis , Giannone Michael A. , Karasic Thomas B. , Furth Emma E. , Carpenter Erica L. , Wojcieszynski Andrzej P. , Vonderheide Robert H. , Beatty Gregory L. , Ben-Josef Edgar
Published: April 2023

Analysis of peripheral blood leukocyte composition among patients with progression and non-progression as best response
Supplementary Figure 1 from Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Authors: Disis Mary L. , Corulli Lauren R. , Gad Ekram A. , Koehnlein Marlese R. , Cecil Denise L. , Senter Peter D. , Gardai Shyra J. , Okeley Nicole M.
Published: April 2023

Outline of study design for Figures 1, 2, 4, and 5, as indicated. Dashed gray line represents treatment with 2FF. Lower line represents general time point in weeks or average mouse age.
Supplementary Dataset 1 from SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status
Authors: Fujihara Kenji M. , Corrales Benitez Mariana , Cabalag Carlos S. , Zhang Bonnie Z. , Ko Hyun S. , Liu David S. , Simpson Kaylene J. , Haupt Ygal , Lipton Lara , Haupt Sue , Phillips Wayne A. , Clemons Nicholas J.
Published: April 2023

Gene List from siRNA screen with APR-246 growth inhibition in H1299 p53-null (Sheet 1) and p53-R273H (Sheet 2)
Supplementary Figure 3 from Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses
Authors: Martomo Stella A. , Lu Dan , Polonskaya Zhanna , Luna Xenia , Zhang Zhikai , Feldstein Sam , Lumban-Tobing Radovan , Almstead Danielle K. , Miyara Faical , Patel Jeegar
Published: April 2023

Heatmap for Changes in Gene Transcription of srKD033/ntKD033 Responder and Non-responder Tumors
Supplemental figure 4 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Authors: Kushibiki Toshihiro , Nakamura Toru , Tsuda Masumi , Tsuchikawa Takahiro , Hontani Koji , Inoko Kazuho , Takahashi Mizuna , Asano Toshimichi , Okamura Keisuke , Murakami Soichi , Kurashima Yo , Ebihara Yuma , Noji Takehiro , Nakanishi Yoshitsugu , Tanaka Kimitaka , Maishi Nako , Sasaki Katsunori , Park Woong-Ryeon , Shichinohe Toshiaki , Hida Kyoko , Tanaka Shinya , Hirano Satoshi
Published: April 2023

Supplemental Figure 4 shows the quantitative graph of AKt phosphorylation and mTOR phosphorylation. (A) AKt phosphorylation in PK-1, PK-9, PANC-1 and MIAPaCa-2 cells. (B) mTOR phosphorylation in PK-1, PK-9, PANC-1 and MIAPaCa-2 cells.
Supplemental figure 2 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Authors: Kushibiki Toshihiro , Nakamura Toru , Tsuda Masumi , Tsuchikawa Takahiro , Hontani Koji , Inoko Kazuho , Takahashi Mizuna , Asano Toshimichi , Okamura Keisuke , Murakami Soichi , Kurashima Yo , Ebihara Yuma , Noji Takehiro , Nakanishi Yoshitsugu , Tanaka Kimitaka , Maishi Nako , Sasaki Katsunori , Park Woong-Ryeon , Shichinohe Toshiaki , Hida Kyoko , Tanaka Shinya , Hirano Satoshi
Published: April 2023

Supplemental Figure 2 shows, (A) analysis of expression of C16orf74 in PDAC and other cancer cell lines by qRT-PCR and (B) analysis of expression of endogenous C16orf74 protein in PDAC and NHDF by Western blot.
Supplemental Table 5 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Authors: Kushibiki Toshihiro , Nakamura Toru , Tsuda Masumi , Tsuchikawa Takahiro , Hontani Koji , Inoko Kazuho , Takahashi Mizuna , Asano Toshimichi , Okamura Keisuke , Murakami Soichi , Kurashima Yo , Ebihara Yuma , Noji Takehiro , Nakanishi Yoshitsugu , Tanaka Kimitaka , Maishi Nako , Sasaki Katsunori , Park Woong-Ryeon , Shichinohe Toshiaki , Hida Kyoko , Tanaka Shinya , Hirano Satoshi
Published: April 2023

RT-PCR primers for construction of the expression vectors
Supplemental Table 1 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Authors: Kushibiki Toshihiro , Nakamura Toru , Tsuda Masumi , Tsuchikawa Takahiro , Hontani Koji , Inoko Kazuho , Takahashi Mizuna , Asano Toshimichi , Okamura Keisuke , Murakami Soichi , Kurashima Yo , Ebihara Yuma , Noji Takehiro , Nakanishi Yoshitsugu , Tanaka Kimitaka , Maishi Nako , Sasaki Katsunori , Park Woong-Ryeon , Shichinohe Toshiaki , Hida Kyoko , Tanaka Shinya , Hirano Satoshi
Published: April 2023

The primer sequences for Quantitative RT-PCR analysis
Supplementary Figuer S3 from Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma
Authors: Ohashi Shinya , Kikuchi Osamu , Nakai Yukie , Ida Tomomi , Saito Tomoki , Kondo Yuki , Yamamoto Yoshihiro , Mitani Yosuke , Nguyen Vu Trang H. , Fukuyama Keita , Tsukihara Hiroshi , Suzuki Norihiko , Muto Manabu
Published: April 2023

Phosphorylated and total CHK1 or CHK2 protein levels in TE-11R cells treated with prexasertib.
Supplementary Data from Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer
Authors: Jones Jill K. , Thompson Eric M.
Published: April 2023

Description of literature search used.
Supplementary Method M1 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
Authors: Nagaraja Shastri Prathap , Zhu Jingjing , Skidmore Lillian , Liang Xuejun , Ji Yanping , Gu Yi , Tian Feng , Yao Sulan , Xia Gang
Published: April 2023

Supplementary Method 1 describes bioanalysis for ARX788, Total Antibody, and pAF-AS269
Figure S3 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Authors: Xu Duo , Liang Shun-Qing , Yang Haitang , Bruggmann Rémy , Berezowska Sabina , Yang Zhang , Marti Thomas Michael , Hall Sean Ralph Robert , Gao Yanyun , Kocher Gregor J. , Schmid Ralph A. , Peng Ren-Wang
Published: April 2023

Supplementary Figure S3. Drug sensitivity to WEE1 inhibitors in MPM and pan-cancer cell lines with different TP53 mutational status
Supplementary Tables from CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
Authors: Kashima Kenji , Kawauchi Hiroki , Tanimura Hiromi , Tachibana Yukako , Chiba Takashi , Torizawa Takuya , Sakamoto Hiroshi
Published: April 2023

Supplementary Tables
Supplementary Figures from CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
Authors: Kashima Kenji , Kawauchi Hiroki , Tanimura Hiromi , Tachibana Yukako , Chiba Takashi , Torizawa Takuya , Sakamoto Hiroshi
Published: April 2023

Supplementary Figures
Supplemental Table 1 from The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Authors: Borden Brittany A. , Baca Yasmine , Xiu Joanne , Tavora Fabio , Winer Ira , Weinberg Benjamin A. , Vanderwalde Ari M. , Darabi Sourat , Korn W. Michael , Mazar Andrew P. , Giles Francis J. , Crawford Lorin , Safran Howard , El-Deiry Wafik S. , Carneiro Benedito A.
Published: April 2023

GSK-3B mutated tumors and PD-L1 expression - non-significant histologies
Suppl. Table S3 from A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells
Authors: Usta Diren , Sigaud Romain , Buhl Juliane L. , Selt Florian , Marquardt Viktoria , Pauck David , Jansen Jennifer , Pusch Stefan , Ecker Jonas , Hielscher Thomas , Vollmer Johanna , Sommerkamp Alexander C. , Rubner Tobias , Hargrave Darren , van Tilburg Cornelis M. , Pfister Stefan M. , Jones David T.W. , Remke Marc , Brummer Tilman , Witt Olaf , Milde Till
Published: April 2023

Suppl. Table S3 shows "Screening for false positive results using the reporter assay without ELK-1 binding site in DKFZ-BT66 and BT-40 cells".
Suppl. Table S2 from A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells
Authors: Usta Diren , Sigaud Romain , Buhl Juliane L. , Selt Florian , Marquardt Viktoria , Pauck David , Jansen Jennifer , Pusch Stefan , Ecker Jonas , Hielscher Thomas , Vollmer Johanna , Sommerkamp Alexander C. , Rubner Tobias , Hargrave Darren , van Tilburg Cornelis M. , Pfister Stefan M. , Jones David T.W. , Remke Marc , Brummer Tilman , Witt Olaf , Milde Till
Published: April 2023

Suppl. Table S2 shows "Overview of MAPKi and other drugs used in the screen".
Supplemental Figure 1 from The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Authors: Borden Brittany A. , Baca Yasmine , Xiu Joanne , Tavora Fabio , Winer Ira , Weinberg Benjamin A. , Vanderwalde Ari M. , Darabi Sourat , Korn W. Michael , Mazar Andrew P. , Giles Francis J. , Crawford Lorin , Safran Howard , El-Deiry Wafik S. , Carneiro Benedito A.
Published: April 2023

Tumor microenvironment in GSK-3B-mutated tumors across histologies.
Suppl. Table S1 from A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells
Authors: Usta Diren , Sigaud Romain , Buhl Juliane L. , Selt Florian , Marquardt Viktoria , Pauck David , Jansen Jennifer , Pusch Stefan , Ecker Jonas , Hielscher Thomas , Vollmer Johanna , Sommerkamp Alexander C. , Rubner Tobias , Hargrave Darren , van Tilburg Cornelis M. , Pfister Stefan M. , Jones David T.W. , Remke Marc , Brummer Tilman , Witt Olaf , Milde Till
Published: April 2023

Suppl. Table S1 shows "List of cloning primers".
Figure S6 from Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis
Authors: Luo Lanxin , Guan Xiudong , Begum Gulnaz , Ding Dawei , Gayden Jenesis , Hasan Md Nabiul , Fiesler Victoria M. , Dodelson Jacob , Kohanbash Gary , Hu Baoli , Amankulor Nduka M. , Jia Wang , Castro Maria G. , Sun Baoshan , Sun Dandan
Published: April 2023

Fig. S6. Combining TMZ therapy with pharmacological inhibition of NKCC1 upregulates GLAST glutamate transporter in tumor-associated reactive astrocytes.
Supplementary Figures S1-S8 from EWS-FLI1–regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth
Authors: Issaq Sameer H. , Mendoza Arnulfo , Kidner Ria , Rosales Tracy I. , Duveau Damien Y. , Heske Christine M. , Rohde Jason M. , Boxer Matthew B. , Thomas Craig J. , DeBerardinis Ralph J. , Helman Lee J.
Published: April 2023

Supplementary Figure S1. PHGDH is highly expressed in Ewing sarcoma cell lines; Supplementary Figure S2. Measurement of PHGDH protein expression. Immunoblot analysis of PHGDH in the specified cell lines expressing lentiviral control shRNA (shControl) or no shRNA (Parental); Supplementary Figure S3. PHGDH knockdown and ES proliferation in vitro; Supplementary Figure S4. Effect of GNE-618 on ES cellular proliferation; Supplementary Figure S5. Dose-effect Curves for GNE-618 and NCT-503; Supplementary Figure S6. Mouse body weight is unaffected by inhibitor treatments; Supplementary Figure S7. EWS-FLI1 is important for sarcoma cellular proliferation in the absence of serine; Supplementary Figure S8. Mouse body weight is unaffected by serine/glycine deficient diet
Supplementary Figures 1-3 from Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
Authors: Gilardi Mara , Wang Zhiyong , Proietto Marco , Chillà Anastasia , Calleja-Valera Juan Luis , Goto Yusuke , Vanoni Marco , Janes Matthew R. , Mikulski Zbigniew , Gualberto Antonio , Molinolo Alfredo A. , Ferrara Napoleone , Gutkind J. Silvio , Burrows Francis
Published: April 2023

Supplementary figure 1. Antitumor activity of tipifarnib in HRAS WT patient-derived xenograft models. Supplementary figure 2. Advaita gene set enrichment analysis. Supplementary figure 3. ENRICHR gene set enrichment analysis.
Supplementary Data from Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
Authors: Gmeiner William H. , Dominijanni Anthony , Haber Alex O. , Ghiraldeli Lais P. , Caudell David L. , D’Agostino Ralph , Pasche Boris C. , Smith Thomas L. , Deng Zhiyong , Kiren Sezgin , Mani Chinnadurai , Palle Komaraiah , Brody Jonathan R.
Published: April 2023

Supplementary data for Gmeiner et al. "Improved anti-tumor activity of CF10.." A total of 13 figures and 4 tables providing analytical data and additional experimental results and summary tables
Supplementary Data from The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells
Authors: Shrestha Rupesh , Mohankumar Kumaravel , Jin Un-ho , Martin Gregory , Safe Stephen
Published: April 2023

Supplemental Table 1, NMR Results, Supplemental Table 2, Supplemental Figures 1 and 2
Supplementary Data from Translational Strategies for Repotrectinib in Neuroblastoma
Authors: O'Donohue Tara J. , Ibáñez Glorymar , Coutinho Diego Ferreira , Mauguen Audrey , Siddiquee Armaan , Rosales Nestor , Calder Paul , Ndengu Andoyo , You Daoqi , Long Matthew , Roberts Stephen S. , Kung Andrew L. , Dela Cruz Filemon S.
Published: April 2023

Supplementary figures and tables
Supplementary Data from Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor
Authors: Banerjee Sudeep , Yoon Hyunho , Yebra Mayra , Tang Chih-Min , Gilardi Mara , Shankara Narayanan Jayanth S. , White Rebekah R. , Sicklick Jason K. , Ray Partha
Published: April 2023

Supplementary Figure 1
Table S2 from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma
Authors: Smeester Branden A. , Draper Garrett M. , Slipek Nicholas J. , Larsson Alex T. , Stratton Natalie , Pomeroy Emily J. , Becklin Kelsie L. , Yamamoto Kenta , Williams Kyle B. , Laoharawee Kanut , Peterson Joseph J. , Abrahante Juan E. , Rathe Susan K. , Mills Lauren J. , Crosby Margaret R. , Hudson Wendy A. , Rahrmann Eric P. , Largaespada David A. , Moriarity Branden S.
Published: April 2023

List of all DEGs identified in transient ZNF217 knockdown versus control SJSA-1 OSA cells with associated fold changes and FDR-adjusted p values.
Supplementary Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma
Authors: Smeester Branden A. , Draper Garrett M. , Slipek Nicholas J. , Larsson Alex T. , Stratton Natalie , Pomeroy Emily J. , Becklin Kelsie L. , Yamamoto Kenta , Williams Kyle B. , Laoharawee Kanut , Peterson Joseph J. , Abrahante Juan E. , Rathe Susan K. , Mills Lauren J. , Crosby Margaret R. , Hudson Wendy A. , Rahrmann Eric P. , Largaespada David A. , Moriarity Branden S.
Published: April 2023

Supplementary data for Smeester et al.
Supplementary Table S3 from A Qualitative Transcriptional Signature for Predicting Prognosis and Response to Bevacizumab in Metastatic Colorectal Cancer
Authors: Yang Jing , Song Kai , Guo Wenbing , Zheng Hailong , Fu Yelin , You Tianyi , Wang Kai , Qi Lishuang , Zhao Wenyuan , Guo Zheng
Published: April 2023

Gene expression profile of genes in GPS-64
Supplementary Figure S3 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Authors: Sullivan Ryan J. , Hollebecque Antoine , Flaherty Keith T. , Shapiro Geoffrey I. , Rodon Ahnert Jordi , Millward Michael J. , Zhang Wei , Gao Ling , Sykes Amanda , Willard Melinda D. , Yu Danni , Schade Andrew E. , Crowe KrisAnne , Flynn Daniel L. , Kaufman Michael D. , Henry James R. , Peng Sheng-Bin , Benhadji Karim A. , Conti Ilaria , Gordon Michael S. , Tiu Ramon V. , Hong David S.
Published: April 2023

Supplementary Figure S3 shows a heatmap of gene expression in the scale of log2 fold ratio between pre- and on-treatment tumor samples. The gene expression was obtained using the formula for a gene g: 2^[20-CT_g+HK]/1000 where CT is the cycle threshold used to detect the gene g. HK is the average over the cycle thresholds used to detect the three housekeeping genes: GUSB, PPIB, and PGK1. The columns of the heatmap represent the 11 target genes. The rows are the five patients labeled with their mutation status. The label is missing if a gene test was not done or not available. Abbreviation: RT-PCR, reverse transcriptase polymerase chain reaction.
Supplementary Figure 2 from Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma
Authors: Ebelt Nancy D. , Zuniga Edith , Passi Kevin B. , Sobocinski Lukas J. , Manuel Edwin R.
Published: April 2023

Supplementary Figure 2 describes the ability of X8768-BHs to degrade HA from fixed human PC-3 prostate cancer cells.
Supplementary Figure S1 from Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth
Authors: Trotta Francesca , Avena Paola , Chimento Adele , Rago Vittoria , De Luca Arianna , Sculco Sara , Nocito Marta C. , Malivindi Rocco , Fallo Francesco , Pezzani Raffaele , Pilon Catia , Lasorsa Francesco M. , Barile Simona N. , Palmieri Luigi , Lerario Antonio M. , Pezzi Vincenzo , Casaburi Ivan , Sirianni Rosa
Published: April 2023

Supplementary Fig. S1 shows that statins affect ACC cell viability
Supplementary Materials and Methods from A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
Authors: Chaturvedi Nagendra K. , Kling Matthew J. , Griggs Connor N. , Kesherwani Varun , Shukla Mamta , McIntyre Erin M. , Ray Sutapa , Liu Yutong , McGuire Timothy R. , Sharp J. Graham , Band Hamid , Joshi Shantaram S. , Coulter Don W.
Published: April 2023

1. Immunohistochemistry (IHC). 2.Histological (H&E) analysis of cerebellar tumors. 3.Magnetic resonance imaging (MRI).
Supplementary Tables from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Authors: Simoneau Antoine , Engel Justin L. , Bandi Madhavi , Lazarides Katherine , Liu Shangtao , Meier Samuel R. , Choi Ashley H. , Zhang Hongxiang , Shen Binzhang , Martires Lauren , Gotur Deepali , Pham Truc V. , Li Fang , Gu Lina , Gong Shanzhong , Zhang Minjie , Wilker Erik , Pan Xuewen , Whittington Douglas A. , Throner Scott , Maxwell John P. , Chen Yingnan , Yu Yi , Huang Alan , Andersen Jannik N. , Feng Tianshu
Published: April 2023

Supplementary Tables S1-S7
Supplementary Figure S3 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Authors: Simoneau Antoine , Engel Justin L. , Bandi Madhavi , Lazarides Katherine , Liu Shangtao , Meier Samuel R. , Choi Ashley H. , Zhang Hongxiang , Shen Binzhang , Martires Lauren , Gotur Deepali , Pham Truc V. , Li Fang , Gu Lina , Gong Shanzhong , Zhang Minjie , Wilker Erik , Pan Xuewen , Whittington Douglas A. , Throner Scott , Maxwell John P. , Chen Yingnan , Yu Yi , Huang Alan , Andersen Jannik N. , Feng Tianshu
Published: April 2023

CRISPR-UMI analysis and characterization of PCNA dynamics - related to Figure 3
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Authors: Iurlaro Raffaella , Waldhauer Inja , Planas-Rigol Ester , Bonfill-Teixidor Ester , Arias Alexandra , Nicolini Valeria , Freimoser-Grundschober Anne , Cuartas Isabel , Martínez-Moreno Alba , Martínez-Ricarte Francisco , Cordero Esteban , Cicuendez Marta , Casalino Simona , Guardia-Reyes Xavier , Fahrni Linda , Pöschinger Thomas , Steinhart Virginie , Richard Marine , Briner Stefanie , Mueller Joerg , Osl Franz , Sam Johannes , Colombetti Sara , Bacac Marina , Klein Christian , Pineda Estela , Reyes-Figueroa Luis , Di Somma Alberto , González Josep , Nuciforo Paolo , Carles Joan , Vieito Maria , Tabernero Josep , Umaña Pablo , Seoane Joan
Published: April 2023

Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Supplementary Data from Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation
Authors: Bariana Manpreet , Cassella Elena , Rateshwar Janice , Ouk Samedy , Liou Hsiou-Chi , Heller Claudia , Colorado Iriana , Feinman Rena , Makhdoom Ali , Siegel David S. , Heller Glenn , Tuckett Andrea , Mondello Patrizia , Zakrzewski Johannes L.
Published: April 2023

Supplementary Data from Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation
Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Authors: Yu Haocheng , Sfakianos John P. , Wang Li , Hu Yang , Daza Jorge , Galsky Matthew D. , Sandhu Harkirat S. , Elemento Olivier , Faltas Bishoy M. , Farkas Adam M. , Bhardwaj Nina , Zhu Jun , Mulholland David J.
Published: April 2023

Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Supplementary Tables from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
Authors: Takano Kohei , Munehira Yoichi , Hatanaka Mana , Murakami Ryo , Shibata Yoshihiro , Shida Takeshi , Takeuchi Kosuke , Takechi Sho , Tabata Toshiki , Shimada Takashi , Kishikawa Shuhei , Matsui Yumi , Ubukata Osamu , Seki Takahiko , Kaneta Yasuyuki
Published: April 2023

Supplementary Tables from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
Supplementary Figures from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
Authors: Takano Kohei , Munehira Yoichi , Hatanaka Mana , Murakami Ryo , Shibata Yoshihiro , Shida Takeshi , Takeuchi Kosuke , Takechi Sho , Tabata Toshiki , Shimada Takashi , Kishikawa Shuhei , Matsui Yumi , Ubukata Osamu , Seki Takahiko , Kaneta Yasuyuki
Published: April 2023

Supplementary Figures from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
Figure S6 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
Authors: Lapadula Dominic , Lam Bao , Terai Mizue , Sugase Takahito , Tanaka Ryota , Farias Eduardo , Kadamb Rama , Lopez-Anton Melisa , Heine Christian C. , Modasia Bhavik , Aguirre-Ghiso Julio A. , Aplin Andrew E. , Sato Takami , Benovic Jeffrey L.
Published: April 2023

Figure S6: Quantification of OMM1.3 cell western blots from Fig. 7. Bands were normalized to GAPDH quantification. Error bars represent the mean + SEM from 3 independent experiments. P < 0.05 (*), P < 0.005 (**), P < 0.0005 (***), P < 0.0001 (****), Two-way ANOVA.
Figure S3 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
Authors: Lapadula Dominic , Lam Bao , Terai Mizue , Sugase Takahito , Tanaka Ryota , Farias Eduardo , Kadamb Rama , Lopez-Anton Melisa , Heine Christian C. , Modasia Bhavik , Aguirre-Ghiso Julio A. , Aplin Andrew E. , Sato Takami , Benovic Jeffrey L.
Published: April 2023

Figure S3: YM treatment of hepatic-metastasis mouse model. A) Experimental scheme. 1.0 x 106 UM001-tdTomato cells were injected into the livers of NSG mice and formed tumors over 5 weeks. B) CT scans of mouse liver containing UM tumors were taken pre-treatment and post 2-week treatment of 0.5 mg/kg YM. Tumors are circled. L = liver, S = spleen. C) Tumor volume was quantified and tumor volume fold change was compared via Mann-Whitney test.
Figure S1 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
Authors: Lapadula Dominic , Lam Bao , Terai Mizue , Sugase Takahito , Tanaka Ryota , Farias Eduardo , Kadamb Rama , Lopez-Anton Melisa , Heine Christian C. , Modasia Bhavik , Aguirre-Ghiso Julio A. , Aplin Andrew E. , Sato Takami , Benovic Jeffrey L.
Published: April 2023

Figure S1: Representative CT images used to calculate tumor volume. Tumor volume was calculated using the following formula: 4π/3 x (a/2) x (b/2) x (c/2) and 3-dimensional images of tumor in the liver. The longest tumor diameter (a) was scaled and then the shortest diameter (b) of the tumor was measured in the Axial view. Z-axis of the tumor (c) was scaled with Coronal view or Sagittal view depending on tumor shape in the liver.
Supplementary Data from Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer
Authors: Bai Shoumei , Taylor Sarah E. , Jamalruddin Mohd Azrin , McGonigal Stacy , Grimley Edward , Yang Dongli , Bernstein Kara A. , Buckanovich Ronald J.
Published: April 2023

Supplementary Data from Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer
Supplementary Table 1 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Authors: Perez Bay Andres E. , Faulkner Devon , DaSilva John O. , Young Tara M. , Yang Katie , Giurleo Jason T. , Ma Dangshe , Delfino Frank J. , Olson William C. , Thurston Gavin , Daly Christopher , Andreev Julian
Published: April 2023

CRISPR RNA gene list
Supplementary Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
Authors: Scherrer Didier , Barrett Noel , Teyton Luc , Pearce Tillman , Nitcheu Josianne , Pouletty Philippe , Santo Julien , Ehrlich Hartmut J.
Published: April 2023

Supplementary Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
Supplementary Figure S2 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Authors: Matsubara Hiroyuki , Miyoshi Hiroyuki , Kakizaki Fumihiko , Morimoto Tomonori , Kawada Kenji , Yamamoto Takehito , Obama Kazutaka , Sakai Yoshiharu , Taketo Makoto Mark
Published: April 2023

Suppl. Fig. S2 with its legend on page 2
Supplementary Tables from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Authors: Mazahreh Rebecca , Mason Marsha L. , Gosink John J. , Olson Devra J. , Thurman Robert , Hale Christopher , Westendorf Lori , Pires Thomas A. , Leiske Christopher I. , Carlson Markus , Nguyen Liem T. , Cochran Julia H. , Okeley Nicole M. , Yumul Roma , Jin Steven , Stone Ivan J. , Sahetya Disha , Nesterova Albina , Allred Sean , Hensley Kelly M. , Hu Rachael , Lawrence Robert , Lewis Timothy S. , Sandall Sharsti
Published: April 2023

Tables S1-S4
Figure S5 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Authors: Umiker Ben , Hashambhoy-Ramsay Yasmin , Smith Jeff , Rahman Tanzila , Mueller Amy , Davidson Rachel , Meyer Christina , Patankar Gayatri , Alam Mohammad Murshid , Jaffe Sarah , Krukenberg Kristin , Goodman Allison , Spaulding Vikki , Priess Michelle , Dhaneshwar Abha , Wong Masie , Diiorio Alexa , O'Malley Kristin , McGrath Lara , Willer Margaret , Pepper Lauren , Gostissa Monica , Kis-Toth Katalin , Wiederschain Dmitri , Cohen Heather , Shaffer Donald R.
Published: April 2023

Example gating strategy in vitro differentiated GM-CSF and IL-4 Dendritic Cells
Figure S10 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Authors: Umiker Ben , Hashambhoy-Ramsay Yasmin , Smith Jeff , Rahman Tanzila , Mueller Amy , Davidson Rachel , Meyer Christina , Patankar Gayatri , Alam Mohammad Murshid , Jaffe Sarah , Krukenberg Kristin , Goodman Allison , Spaulding Vikki , Priess Michelle , Dhaneshwar Abha , Wong Masie , Diiorio Alexa , O'Malley Kristin , McGrath Lara , Willer Margaret , Pepper Lauren , Gostissa Monica , Kis-Toth Katalin , Wiederschain Dmitri , Cohen Heather , Shaffer Donald R.
Published: April 2023

Pembrolizumab pharmacodynamic response in histoculture as measured by IFN gamma signature score
Figure S1 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Authors: Umiker Ben , Hashambhoy-Ramsay Yasmin , Smith Jeff , Rahman Tanzila , Mueller Amy , Davidson Rachel , Meyer Christina , Patankar Gayatri , Alam Mohammad Murshid , Jaffe Sarah , Krukenberg Kristin , Goodman Allison , Spaulding Vikki , Priess Michelle , Dhaneshwar Abha , Wong Masie , Diiorio Alexa , O'Malley Kristin , McGrath Lara , Willer Margaret , Pepper Lauren , Gostissa Monica , Kis-Toth Katalin , Wiederschain Dmitri , Cohen Heather , Shaffer Donald R.
Published: April 2023

Tumor samples used in flow cytometry analysis, in this table the tumor type, the pathology, the total events and the number of CD11b+ cells are shown
Supplementary Figure 4 from Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Authors: Bordeau Brandon M. , Nguyen Toan Duc , Polli Joseph Ryan , Chen Ping , Balthasar Joseph P.
Published: April 2023

Supplementary Figure 4
Supplementary Figure 3 from Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Authors: Bordeau Brandon M. , Nguyen Toan Duc , Polli Joseph Ryan , Chen Ping , Balthasar Joseph P.
Published: April 2023

Supplementary Figure 3
Supplementary Figure 2 from Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Authors: Bordeau Brandon M. , Nguyen Toan Duc , Polli Joseph Ryan , Chen Ping , Balthasar Joseph P.
Published: April 2023

Supplementary Figure 2
Data from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Authors: Niwa Yuki , Adachi Keito , Tabata Kimiyo , Ishida Ryoga , Hotta Koichiro , Ishida Tomomi , Mano Yuji , Ozawa Yoichi , Minoshima Yukinori , Funahashi Yasuhiro , Semba Taro
Published: April 2023

Abstract
Eribulin is a microtubule dynamics inhibitor with tumor microenvironment modulation activity such as vascular remodeling activity. Here, we investigated antitumor and immunomodulatory activities of eribulin and its liposomal formulation (eribulin-LF) as monotherapies or in combination with anti–programmed death 1 (PD-1) Ab. The antitumor activity of eribulin or eribulin-LF as monotherapy or in combination with anti–PD-1 Ab was examined in a P-glycoprotein–knockout 4T1 model. Eribulin and eribulin-LF showed stronger antitumor activity in immunocompetent mice compared with immunodeficient mice, indicating that they have immunomodulatory activity that underlies its antitumor activity. Combination therapy of eribulin and eribulin-LF with anti–PD-1 Ab showed antitumor activity, and the combination activity of eribulin-LF with anti–PD-1 Ab was observed at a lower dose and longer interval of administration compared with that using eribulin. To examine the immunomodulatory activity of eribulin and eribulin-LF and its underlying mechanisms, we performed flow cytometry, IHC, and gene expression profiling. IHC and flow cytometry revealed that eribulin-LF increased microvessel density and intratumoral populations of cytotoxic T cells and natural killer cells rather than eribulin. Gene expression profiling demonstrated that eribulin-LF induces IFNγ signaling. Furthermore, IHC also showed that eribulin-LF increased infiltration of CD8-positive cells together with increased CD31-positive cells. Eribulin-LF also increased ICAM-1 expression, which is essential for lymphocyte adhesion to vascular endothelial cells. In conclusion, eribulin showed combination antitumor activity with anti–PD-1 Ab via immunomodulation due to its vascular remodeling activity, and the liposomal formulation showed improved antitumor activity over the standard formulation.
Data from Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors
Authors: Zhang Qiang , Xu Jianghao , Qian Yi , Chen Liang , Li Qingya , Xu Kangjing , Chen Ming , Sun Luning , He Zhongyuan , Yang Li , Zhang Diancai , Wang Linjun , Sun Xiaofeng , Wang Yongqing , Xu Hao , Xu Zekuan
Published: April 2023

Abstract
Gastrointestinal stromal tumors (GIST) are the most prevalent mesenchymal tumors of the digestive tract. To investigate the association of imatinib mesylate plasma concentration with adverse drug reactions (ADRs) and influences of genetic polymorphisms on ADRs in GIST patients taking imatinib, a cohort of GIST patients consecutively treated with imatinib were included in the observational study. Clinical, pathologic and genotype information was recorded at enrollment and blood samples were collected at time as design. The plasma concentration of the imatinib was detected by LC-MS/MS. A questionnaire was used to evaluate the ADRs at each visit. SNPs in 13 genes were analyzed for a possible association with ADRs. The mean plasma trough concentration of 129 patients taking imatinib was 1.45 ± 0.79 μg/ml, average peak concentration was 2.63 ± 1.07 μg/ml. The imatinib concentration in patients treated with 600 mg/day was significantly higher than other dosage groups (P < 0.05). The ADRs were mostly mild. Edema, vomiting, and fatigue were significantly correlated with imatinib concentration (P < 0.05). Mutations of IL13 rs1800925 and CXCL14 rs7716492 were related with the incidence of leukopenia and rash in our research, separately (P < 0.05). We confirmed that with the increase of imatinib concentration, the incidence of edema, vomiting, and fatigue rises as well. Mutations of IL13 rs1800925 and CXCL14 rs7716492 may be the promising biomarkers to predict the ADRs of imatinib. The results of the study are of guiding significance for the use of imatinib in patients with GIST.
Data from Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer
Authors: Hata Tsuyoshi , Rajabi Hasan , Yamamoto Masaaki , Jin Caining , Ahmad Rehan , Zhang Yan , Kui Ling , Li Wei , Yasumizu Yota , Hong Deli , Miyo Masaaki , Hiraki Masayuki , Maeda Takahiro , Suzuki Yozo , Takahashi Hidekazu , Samur Mehmet , Kufe Donald
Published: April 2023

Abstract
The oncogenic MUC1-C protein and the TWIST1 epithelial–mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the TWIST1 gene. In turn, MUC1-C binds directly to TWIST1, and MUC1-C/TWIST1 complexes activate MUC1-C expression in an autoinductive circuit. The functional significance of the MUC1-C/TWIST1 circuit is supported by the demonstration that this pathway is sufficient for driving (i) the EMT-TFs, ZEB1 and SNAIL, (ii) multiple genes in the EMT program as determined by RNA-seq, and (iii) the capacity for cell invasion. We also demonstrate that the MUC1-C/TWIST1 circuit drives (i) expression of the stem cell markers SOX2, BMI1, ALDH1, and CD44, (ii) self-renewal capacity, and (iii) tumorigenicity. In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance. Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells. These findings uncover a master role for MUC1-C in driving the induction of TWIST1, EMT, stemness, and drug resistance, and support MUC1-C as a highly attractive target for inhibiting TNBC plasticity and progression.
Data from IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma
Authors: Cardillo Thomas M. , Govindan Serengulam V. , Zalath Maria B. , Rossi Diane L. , Wang Yang , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Abstract
HLA-DR is a member of the MHC class II antigen family expressed on hematologic and solid tumors. Antibodies directed against HLA-DR have demonstrated some clinical success, but toxicities limited development. IMMU-140 is an anti–HLA-DR antibody–drug conjugate composed of the active metabolite of irinotecan, SN-38, conjugated to a humanized anti–HLA-DR IgG4 antibody (IMMU-114); the IgG4 naked antibody is devoid of immune functions. Our aim was to determine if SN-38, the metabolite of a drug not commonly used in hematopoietic cancers, would be effective and safe when targeted to HLA-DR–expressing tumors. IMMU-140 had dual-therapeutic mechanisms, as evidenced by its retention of nonoverlapping anti–HLA-DR nonclassical apoptotic signaling and classical apoptosis mediated by its SN-38 payload. In seven human disease models [acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and melanoma], IMMU-140 provided significant therapeutic efficacy compared with controls, in vitro, in 3D spheroid models, and in vivo. Except for MM and HL, IMMU-140 imparted significantly improved antitumor effects compared with parental IMMU-114. Even in intractable AML and ALL, where IMMU-114 only had modest antitumor effects, IMMU-140 therapy mediated >80% improvement in survival. Therapy was well tolerated, as demonstrated by no marked loss in body weight. Combined with doxorubicin, IMMU-140 produced significantly greater antitumor effects in HL than with monotherapy and without any added toxicity. The dual-therapeutic action of IMMU-140 resulted in promising therapeutic activity in a range of hematopoietic tumors and melanoma, and therefore warrants clinical development. Mol Cancer Ther; 17(1); 150–60. ©2017 AACR.
Data from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Authors: Huang Yan , Hu Wei , Huang Jie , Shen Fangrong , Sun Yunjie , Ivan Cristina , Pradeep Sunila , Dood Robert , Haemmerle Monika , Jiang Dahai , Mangala Lingegowda S. , Noh Kyunghee , Hansen Jean M. , Dalton Heather J. , Previs Rebecca A. , Nagaraja Archana S. , McGuire Michael , Jennings Nicholas B. , Broaddus Russell , Coleman Robert L. , Sood Anil K.
Published: April 2023

Abstract
Although progesterone receptor (PR)–targeted therapies are modestly active in patients with uterine cancer, their underlying molecular mechanisms are not well understood. The clinical use of such therapies is limited because of the lack of biomarkers that predict response to PR agonists (progestins) or PR antagonists (onapristone). Thus, understanding the underlying molecular mechanisms of action will provide an advance in developing novel combination therapies for cancer patients. Nuclear translocation of PR has been reported to be ligand-dependent or -independent. Here, we identified that onapristone, a PR antagonist, inhibited nuclear translocation of ligand-dependent or -independent (EGF) phospho-PR (S294), whereas trametinib inhibited nuclear translocation of EGF-induced phospho-PR (S294). Using orthotopic mouse models of uterine cancer, we demonstrated that the combination of onapristone and trametinib results in superior antitumor effects in uterine cancer models compared with either monotherapy. These synergistic effects are, in part, mediated through inhibiting the nuclear translocation of EGF-induced PR phosphorylation in uterine cancer cells. Targeting MAPK-dependent PR activation with onapristone and trametinib significantly inhibited tumor growth in preclinical uterine cancer models and is worthy of further clinical investigation. Mol Cancer Ther; 17(2); 464–73. ©2017 AACR.